Simulations Plus (SLP) witnessed a pre-market plunge of 9.84% on Wednesday, potentially driven by concerns surrounding the company's latest earnings report and an analyst downgrade.
The biopharmaceutical company reported its Q1 2025 earnings on Tuesday evening, showcasing robust growth. However, it appears that some investors were not fully satisfied with the results, leading to a selloff in the pre-market session.
Additionally, KeyBanc lowered its price target on Simulations Plus to $35 from $40, while maintaining an Overweight rating. This analyst action could have further fueled the negative sentiment surrounding the stock.